## [Manufacturing](/about/manufacturing "Manufacturing") Novartis delivers transformative innovation through the manufacture and supply of high-quality medicines. Operating in more than 30 production sites worldwide, our sites are fully focused on producing innovative medicines across our technology platforms – Small Molecules, Large Molecules, Aseptic Drug Product, Cell & Gene therapies and Radioligand therapies. Overall, we manufactured over 20 billion treatments in 2025, ensuring a continuous and reliable supply of our medicines to patients. From planning and procurement to manufacturing and logistics we leverage the latest digital technologies with the mindset to improve supply chain efficiency, making operations smoother, faster and more accurate. We do all this without ever compromising the foundations of our success: quality, safety, compliance and our commitment to sustainability. ![Steffen Lang - President, Operations](/sites/novartis_com/files/styles/cta_image/public/2025-01/steffen-lang-1170.jpg.webp?itok=WDr3FrFZ "Steffen Lang - President, Operations") > At Novartis, manufacturing is more than a capability, it’s a commitment. Every treatment we produce reflects the passion, precision, and purpose of our people. Together, we deliver innovation at scale and life-changing treatments to patients around the world. > > — **Steffen Lang**, President Operations ![Manufacturing production specialist](/sites/novartis_com/files/styles/cta_image/public/2025-10/manufacturing-novartis-production-specialist.png.webp?itok=2zKru4Y8 "Manufacturing production specialist") ## Recognized for excellence in manufacturing & supply We are proud that Novartis Manufacturing & Supply has been recognized in the 2026 rankings for [Gartner Global Supply Chain Top 25](https://www.gartner.com/en/newsroom/press-releases/2026-06-17-gartner-announces-2026-rankings-of-the-global-supply-chain-top-25) and the 2025 [Alcott Leaders in Supply Chain Award](https://gala.makersmovers.com/top-30-winners-of-2025/top-12-steffen-lang/). These accolades reflect our commitment to innovation, resilience and quality in delivering medicines to patients worldwide. ![Manufacturing site solar panels](/sites/novartis_com/files/styles/cta_image/public/2025-10/manufacturing-site-solar-panels.png.webp?itok=geEK-KnQ "Manufacturing site solar panels") ## Environmental Sustainability At Novartis, sustainability is embedded in how we manufacture and supply medicines. From reducing emissions to optimizing energy use, our operations are designed to support a healthier planet while delivering life-changing therapies at scale. [Learn more](/esg/environmental-sustainability "Learn more") [ ![Woman scientist in lab](/sites/novartis_com/files/styles/cards_50_50/public/2022-02/woman-scientist-lab-1920x620.jpg.webp?itok=BfRfztza "Woman scientist in lab") ### Contract manufacturing At Novartis, we partner with highly-regarded pharmaceutical and biotech companies globally as a contract development and manufacturing (CDMO) partner, bringing medical innovation to life together. ](/about/manufacturing/contract-manufacturing) [ ![Production Specialists Walking](/sites/novartis_com/files/styles/cards_50_50/public/2022-02/production-specialists-walking.jpg.webp?itok=_gY4VKb9 "Production Specialists Walking") ### Careers in Manufacturing and Supply Learn more about careers in manufacturing, supply and quality, explore opportunities and apply for open positions. ](/careers) ![Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida](/sites/novartis_com/files/styles/cta_image/public/2025-01/portrait-of-kate-kostelyk-and-her-labrador.jpg.webp?itok=4HIqaVLd "Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida") ## Transforming manufacturing The Novartis Report on Nonfinancial Matters 2025 describes how our manufacturing operations are evolving as we embrace operational excellence. [Learn more](/sites/novartis_com/files/novartis-report-nonfinancial-matters-2025.pdf "Learn more") ### Quality Quality is a key priority in every aspect of our work. Our patients are relying on us to deliver the highest quality standards, and we are committed to living up to their expectations. [Learn more](/about/quality "Learn more") ## Our News [Novartis to build new radioligand therapy site in Texas, US](/news/media-releases/novartis-build-new-radioligand-therapy-site-denton-texas-delivering-more-next-generation-treatments-patients "Novartis to build new radioligand therapy site in Texas, US") [Novartis breaks ground on new global Biomedical Research center in California, US](/news/media-releases/novartis-breaks-ground-new-global-biomedical-research-center-san-diego-accelerate-drug-discovery "Novartis breaks ground on new global Biomedical Research center in California, US") [Novartis plans to build RLT manufacturing facility in Florida, US](/news/media-releases/novartis-add-radioligand-therapy-manufacturing-facility-winter-park-florida-fourth-us-serve-patients-and-advance-23-billion-investment "Novartis plans to build RLT manufacturing facility in Florida, US") [Novartis announces plans to build flagship manufacturing hub in North Carolina](/news/media-releases/novartis-announces-plans-build-flagship-manufacturing-hub-north-carolina "Novartis announces plans to build flagship manufacturing hub in North Carolina") [Novartis opens new radioligand therapy manufacturing facility in California](/news/media-releases/novartis-opens-new-radioligand-therapy-manufacturing-facility-california-part-23b-us-expansion-plan "Novartis opens new radioligand therapy manufacturing facility in California") [Investing in America’s Health](https://www.novartis.com/us-en/about/investing-americas-health "Investing in America’s Health") [Novartis plans to expand its US-based manufacturing](https://www.novartis.com/us-en/news/media-releases/novartis-plans-expand-its-us-based-manufacturing-and-rd-footprint-total-investment-23b-over-next-5-years "Novartis plans to expand its US-based manufacturing") [Novartis opens first viral vector facility in Europe](https://www.novartis.com/si-en/news/media-releases/slovenia-novartis-opens-its-first-specialized-viral-vector-production-facility-europe "Novartis opens first viral vector facility in Europe") Novartis is a global company and its policies and programs, including those described in the Novartis in Society Integrated Report, may differ depending on the jurisdiction in which it operates. Novartis is committed to complying with the law in the countries and jurisdictions in which it conducts business.